Gene · 2176
Papers2,586
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,586
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Chronic Coronary Disease. | J Cardiovasc Magn Reson | 2023 | 37858155 | PubTator, text mining | PubMed |
| Next-generation sequencing in dermatology. | Front Med (Lausanne) | 2023 | 37841001 | PubTator, text mining | PubMed |
| An Analysis of Optical Coherence Tomography Angiography (OCT-A) Perfusion Density Maps in Patients Treated for Retinal Vein Occlusion with Intravitreal Aflibercept. | Diagnostics (Basel) | 2023 | 37835843 | PubTator, text mining | PubMed |
| Development of Engineered-U1 snRNA Therapies: Current Status. | Int J Mol Sci | 2023 | 37834063 | PubTator, text mining | PubMed |
| [BRCA-like breast cancer patients benefit from cisplatin plus veliparib-results from the S1416 phase II study]. | Strahlenther Onkol | 2023 | 37823898 | PubTator, text mining | PubMed |
| FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma. | Eur J Med Res | 2023 | 37821996 | PubTator, text mining | PubMed |
| Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays. | NPJ Precis Oncol | 2023 | 37821580 | PubTator, text mining | PubMed |
| UCHL1-PKM2 axis dysregulation is associated with promoted proliferation and invasiveness of urothelial bladder cancer cells. | Aging (Albany NY) | 2023 | 37815895 | PubTator, text mining | PubMed |
| Facies analysis, biostratigraphy, and provenance of the late Neogene Seulimeum Formation, Northwest Aceh basin, Sumatra (Indonesia). | Heliyon | 2023 | 37809546 | PubTator, text mining | PubMed |
| [Diagnosis status and genetic characteristics analysis of Fanconi anemia in China]. | Zhonghua Er Ke Za Zhi | 2023 | 37803855 | PubTator, text mining | PubMed |
| Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. | NPJ Breast Cancer | 2023 | 37803017 | PubTator, text mining | PubMed |
| Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls. | Front Genet | 2023 | 37790698 | PubTator, text mining | PubMed |
| Homologous Recombination Abnormalities Associated With BRCA1/2 Mutations as Predicted by Machine Learning of Targeted Next-Generation Sequencing Data. | Breast Cancer (Auckl) | 2023 | 37789896 | PubTator, text mining | PubMed |
| Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. | Nat Med | 2023 | 37783966 | PubTator, text mining | PubMed |
| Reduced FANCE Confers Genomic Instability and Malignant Behavior by Regulating Cell Cycle Progression in Endometrial Cancer. | J Cancer | 2023 | 37779877 | PubTator, text mining | PubMed |
| The Tumor Suppressor BRCA1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers. | Asian Pac J Cancer Prev | 2023 | 37774066 | PubTator, text mining | PubMed |
| Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma. | J Clin Med | 2023 | 37762710 | PubTator, text mining | PubMed |
| Simultaneous Occurrence of Multiple Neoplasms in Children with Cancer Predisposition Syndromes: Collaborating with Abnormal Genes. | Genes (Basel) | 2023 | 37761810 | PubTator, text mining | PubMed |
| The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking. | Diagnostics (Basel) | 2023 | 37761329 | PubTator, text mining | PubMed |
| The Fanconi anemia core complex promotes CtIP-dependent end-resection to drive homologous recombination at DNA double-strand breaks. | bioRxiv | 2023 | 37732274 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2176/papers?page=9